| Revenue growth | 42% YoY growth driven by JB Pharma acquisition and India business. |
|---|---|
| Margins | EBITDA margins maintained at 32.7% despite integration costs. |
| Demand visibility | Strong visibility in India chronic and Curatio portfolio demand. |
| Management confidence | High, particularly regarding synergy realization and India market outperformance. |
Growth
Consolidated revenue rose 42% YoY; organic base business grew 16% with robust chronic segment performance.
Outlook
Targeting 10-15% India growth and 7,500 total MR strength in FY27.
Risks
Middle East geopolitical tension impacting JB's international business and supply disruptions in Germany.
Earnings Call filed with NSE, NSE: TORNTPHARM. Summary written with AI assistance from the document.
Torrent Pharmaceuticals Ltd: key numbers
- Share price
- ₹4,988.50
- Market cap
- ₹1,89,747 Cr
- Revenue (annual)
- ₹13,980 Cr
- Net profit (annual)
- ₹2,163 Cr
- P/E (TTM)
- 87.0×Sector 50.4×
- Promoter holding
- 60.78%-7.53% QoQ
- FII holding
- 17.97%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Torrent Pharmaceuticals Ltd
All →Torrent Pharmaceuticals Annual General Meeting
Shareholders approved the appointment of Ms. Shanti Ekambaram as an Independent Director of Torrent Pharmaceuticals via Postal Ballot.
Torrent Pharmaceuticals Earnings Call Transcript: Key Takeaways
Torrent Pharma delivered strong Q1 performance with revenues up 55% following the JB Chemicals merger completion. EBITDA margins jumped to 33.8% driven by accelerated cost synergies.
- Call
- Guides 10% growth
Torrent Pharmaceuticals Q1 FY27 Results: Net Profit ₹566 Cr, Up 3.3% YoY
Torrent Pharmaceuticals Ltd reported revenue from operations of ₹4,921 Cr (+54.8% YoY) and net profit of ₹566 Cr (+3.3% YoY) for Q1 FY27.
- Key figure
- Net profit ₹566 Cr · +3.3% YoY
Torrent Pharmaceuticals Earnings Call: Key Takeaways
Torrent Pharma Q4 FY26 revenue rose 42% to ₹4,197cr, driven by JB Pharma consolidation. Combined EBITDA margin stood at 32.3%, with focus on Semaglutide ramp-up in India and synergy execution.
Torrent Pharmaceuticals Q4 FY26 Results: Net Profit ₹364 Cr, Down 26.9% YoY
Torrent Pharmaceuticals Ltd reported revenue from operations of ₹4,197 Cr (+41.8% YoY) and net profit of ₹364 Cr (-26.9% YoY) for Q4 FY26.
- Key figure
- Net profit ₹364 Cr · -26.9% YoY